The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects

Nateglinide (Starlix, SDZ DJN 608 or A-4166), a new insulinotropic agent, is intended to be administered prior to a meal in order to improve early insulin release in non-insulin-dependent diabetes mellitus patients. The effects of a meal on the oral bioavailability and pharmacodynamic actions of nateglinide were investigated. Twelve healthy male subjects completed this randomized, single-dose, four-way crossover study in which each subject received a 60 mg dose of nateglinide 10 minutes before the start of and immediately after a high-fat breakfast meal. In addition, each subject received a single 30 and 60 mg dose of nateglinide underfasting conditions. Plasma and urine concentrations of nateglinide were determined by an HPLC method while plasma glucose and insulin concentrations were measured by standard immunoassay methods. Compared to the fasted state, administration of nateglinide 10 minutes before the meal was associated with an increase in the rate of absorption (12% increase in Cmax and 52% decrease in tmax), while there was no significant effect on the extent of absorption (AUC). Alternatively, when nateglinide was given after the meal, a food effect was observed that was characterized by a decrease in the rate of absorption: 34% decrease in Cmax and a 22% increase in tmax but no significant effect on AUC. Nateglinide was rapidly eliminated with plasma t 1/2 = 1.4 hours. Its plasma renal clearance, 20.7 ml/min, appears to be due mostly to active tubular secretion. However, only 13% to 14% of the dose is recovered as nateglinide in the urine. The 30 and 60 mg tablets were dose proportional in terms of both AUC and Cmax; both tmax and t 1/2 were dose independent. Regardless of timing, the combination of a meal and nateglinide produced a larger increase in insulin levels than did nateglinide alone. Meal-related glucose excursions were eliminated when nateglinide was taken prior to the meal. Thus, the rapid onset/short duration stimulation of insulin release by nateglinide should allow good control of prandial hyperglycemia while limiting exposure to hyperinsulinemia.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. A. Spiller and T. S. Sawyer Toxicology of oral antidiabetic medications Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 929 - 938. [Abstract] [Full Text] [PDF]

				C. Abletshauser, P. Brunel, K.-H. Usadel, and M. Hanefeld Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 93 - 99. [Abstract] [PDF]

				D. Devineni, Y. H. Walter, H. T. Smith, J. S. Lee, P. Prasad, and J. F. McLeod Pharmacokinetics of Nateglinide in Renally Impaired Diabetic Patients J. Clin. Pharmacol., February 1, 2003; 43(2): 163 - 170. [Abstract] [Full Text]

				M. L. Weaver, B. A. Orwig, L. C. Rodriguez, E. D. Graham, J. A. Chin, M. J. Shapiro, J. F. McLeod, and J. B. Mangold Pharmacokinetics and Metabolism of Nateglinide in Humans Drug Metab. Dispos., April 1, 2001; 29(4): 415 - 421. [Abstract] [Full Text]

				J. B. Kalbag, Y. H. Walter, J. R. Nedelman, and J. F. McLeod Mealtime Glucose Regulation With Nateglinide in Healthy Volunteers: Comparison with repaglinide and placebo Diabetes Care, January 1, 2001; 24(1): 73 - 77. [Abstract] [Full Text]

				L. Keilson, S. Mather, Y. H. Walter, S. Subramanian, and J. F. McLeod Synergistic Effects of Nateglinide and Meal Administration on Insulin Secretion in Patients with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1081 - 1086. [Abstract] [Full Text]